A Ludwig Cancer Research study has identified a novel strategy for treating acute myelogenous leukemia (AML), an aggressive ...

A Ludwig Cancer Research study has identified a novel strategy for treating acute myelogenous leukemia (AML), an aggressive ...

People at high risk of acute myeloid leukaemia (AML) can be identified years in advance, but there is currently no treatment ...

A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...

However, it has proven difficult to identify such specific antigens in certain cancer types, including acute myeloid leukemia (AML). AML patients are often treated using allogeneic hematopoietic stem ...

However, we found that most acute myeloid leukemia (AML) cells, especially M4 and M5 subtypes, produce TNF and show basal level activation of RIP1/RIP3/MLKL signaling, yet do not undergo necroptosis.

Acute myeloid leukemia (AML) is a cancer that impacts the blood and bone marrow ... This overproduction crowds out normal blood cells, leading to symptoms such as fatigue, frequent infections, and ...

Aug. 21, 2024 — An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth. AML cells prevent the synthesis of proteins that ...

Acute myeloid leukemia (AML) is one of the most common types of leukaemia among adults. A major challenge in developing chimeric antigen receptor (CAR)-engineered cell therapies for acute myeloid ...

A team of scientists from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has identified a promising new drug target for acute myeloid leukemia (AML), a deadly ...